4-Isopropyl-Δ⁴-thiazolinthion-(2) | 33120-79-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-Isopropyl-Δ⁴-thiazolinthion-(2)
• 英文别名: 5-Isopropyl-thiazolin-thion(2)；4-isopropyl-3H-thiazole-2-thione；2(3H)-Thiazolethione, 4-(1-methylethyl)-；4-propan-2-yl-3H-1,3-thiazole-2-thione
• CAS: 33120-79-5
• 化学式: C₆H₉NS₂
• 分子量: 159.276
• InChiKey: BACKYMNXXFPCRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  69.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-Isopropyl-Δ⁴-thiazolinthion-(2) 在 potassium tert-butylate 、 水 、 铁粉 、 氯化铵 作用下， 以 乙醇 、 叔丁醇 为溶剂， 反应 76.0h， 生成 6-Amino-5-(4-isopropyl-thiazol-2-ylsulfanyl)-benzofuran-3-one
  参考文献：
  名称：

  A Convergent Route to 5-(Arylsulfanyl)-6-sulfonamido-3-benzofuranones

  摘要：

  已开发出一种合成5-(芳基硫基)-2,3-二氢-6-磺酰氨基-3-苯并呋喃酮（1）的程序，该合成以5溴-3-甲氧基-6-硝基苯并呋喃（4）作为共先进合成中间体。关键步骤是4中溴原子的区域选择性亲核芳香取代反应，取代反应中使用芳基或杂芳基硫醇。

  DOI：

  10.1055/s-2000-6396

文献信息

• Novel 2-pyridinecarboxamide derivatives
  申请人：Mitsuya Morihiro

  公开号：US20060258701A1

  公开（公告）日：2006-11-16

  The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

  本发明涉及一种化合物，具有激活葡萄糖激酶的效果，并可用作糖尿病治疗剂，其化学式表示为（I）：[其中X1表示氮原子、硫原子、氧原子或类似物；R1表示6-至10-成员芳基基团、5-至7-成员杂芳基基团或类似物；D表示氧原子或硫原子；R和R3相同或不同，分别表示氢原子、低碳基或类似物；式（II）表示可选取代的5-至7-成员杂芳基团或类似物；式（III）表示单环或双环杂芳基团]或其药学上可接受的盐。
• NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES
  申请人：MITSUYA MORIHIRO

  公开号：US20100041660A1

  公开（公告）日：2010-02-18

  The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R 2 and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.

  本发明涉及一种具有葡萄糖激酶激活作用并且可用作糖尿病治疗剂的化合物，其化学式为（I）：[其中X1代表氮原子、硫原子、氧原子或类似物；R1代表6到10个成员的芳基基团、5到7个成员的杂芳基团或类似物；D代表氧原子或硫原子；R2和R3相同或不同，每个代表氢原子、低碳基团或类似物；化学式（II）代表可选取代的5到7个成员的杂芳基团或类似物；化学式（III）代表单环或双环杂芳基团]或其药学上可接受的盐。
• Synthesis and biological properties of a new series of anti-MRSA β-lactams; 2-(thiazol-2-ylthio)carbapenems
  作者：Hisatoshi Shinagawa、Hiroshi Yamaga、Hitoshi Houchigai、Yoshihiro Sumita、Makoto Sunagawa

  DOI：10.1016/s0968-0896(96)00273-8

  日期：1997.3

  A series of 1 beta-methylcarbapenems containing variously C-2 substituted thiazol-2-ylthio groups were synthesized, and their in vitro anti-MRSA activity was examined. Among them, 1 beta-methyl-2-(4-arylthiazol-2-ylthio) carbapenems exhibited superior anti-MRSA activity. Introduction of a cationic moiety in the C-2 side chain not only reduced the binding to HSA but also increased the stability against DHP-I, without affecting the anti-MRSA, activity. It was also found that the distance between the cationic moiety and the carbapenem skeleton was related to the strength of HSA binding and the stability against DHP-I. (C) 1997 Elsevier Science Ltd.
• COMPOUNDS FOR TREATMENT OF CANCER
  申请人：ONCTERNAL THERAPEUTICS, INC.

  公开号：US20220024912A1

  公开（公告）日：2022-01-27

  The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.
• US3931060A
  申请人：——

  公开号：US3931060A

  公开（公告）日：1976-01-06